Penpulimab Combined With CRT

PreclinicalSmall molecule

Penpulimab Combined With CRT is one of 3 small molecule programs targeting Esophageal Squamous Cell Cancer. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Esophageal Squamous Cell CancerUnknown status

Esophageal Squamous Cell CancerPreclinical

Unknown status

Competition

Competitive Landscape

3 competitors in Esophageal Squamous Cell Cancer

#DrugCompanyPhaseTrials

Chemotherapy Followed Dendritic Cells

SShanghai Chest Hospital

Phase 2

1 2

Penpulimab Combined With CRT

SShanghai Zhongshan Hospital

Preclinical

1 3

Induction Chemo-Immunotherapy

SSun Yat-sen University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Esophageal Squamous Cell Cancer1 trial

Sequential Preoperative Penpulimab Combined With Chemoradiotherapy(CRT) for Locally Advanced Esophageal Squamous Cell Cancer

Unknown status·SShanghai Zhongshan Hospital·N/A·NCT05561699·66 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Penpulimab Combined With CRT. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Penpulimab Combined With CRT compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Penpulimab Combined With CRT. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai Zhongshan Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: SShanghai Zhongshan Hospital

Penpulimab Combined With CRT

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Esophageal Squamous Cell Cancer1 trial

References

Drug Info

Quick Facts

Related News